News

Actelion Pharmaceuticals Ltd recently announced in a press release that new data on its investigational drug selexipag (Uptravi®) and the approved macitentan (Opsumit®) for pulmonary arterial hypertension will be presented at the upcoming European Society of Cardiology (ESC) Congress in London, United Kingdom, August 29 to September…

In a new study entitled “Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice,” researchers investigated the role of the vagus nerve in pulmonary fibrosis pathogenesis. They established a mouse model and discovered that the vagus nerve regulates pulmonary fibrosis progression by controlling pro-fibrotic factors. The study was published in…

Results from a recent study published in the journal Circulation: Cardiovascular Imaging showed that pediatric patients with Pulmonary hypertension have reduced Left Ventricular  strain/strain rate, predominantly within the septum, with relationships to invasive hemodynamics, right ventricular strain, and functional Pulmonary hypertension measures. Pulmonary hypertension (PH) is raised…

A new study recently published in the Chinese Medical Journal revealed that a 6-month warfarin treatment might not be sufficient as an effective therapy for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome (OSAHS). The study was conducted by researchers at Beijing Anzhen Hospital…

A new study published in the Journal of Cardiovascular Ultrasound revealed a new parameter linked to right ventricular function as a good prognostic tool for pulmonary arterial hypertension (PAH). The study is entitled “Impaired Global Right Ventricular Longitudinal Strain Predicts Long-Term Adverse Outcomes in…

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company focused on addressing rare, chronic, and serious inflammatory and fibrotic diseases, recently announced that the US Food and Drug Administration has granted its orally-available CB2 receptor agonist Resunab Fast Track Development status for systemic sclerosis. With the FDA’s Fast Track Designation, Corbus will be…

Researchers at the University of Alberta in Canada published an article in the journal Cell Metabolism concerning pulmonary arterial hypertension (PAH) and details on a new theory suggesting that the disorder should be seen as a syndrome affecting several organs at the metabolic level. The study…

A new study led by researchers at Peking Union Medical College Hospital in China recently revealed that resveratrol can prevent pulmonary arterial hypertension (PAH) through a protein called SIRT1 (silence information regulator 1) in vitro and in rat models. The study was published in the journal…

A study recently published in the International Journal of Chronic Obstructive Pulmonary Disease emphasized that patients with arterial hypertension can be considered a risk group for chronic obstructive pulmonary disease (COPD) and should be screened for the disorder even in the absence of respiratory symptoms. The study…

An international group of researchers are currently recruiting participants for Sanofi’s Phase 2 trial of SAR156597 for the treatment of idiopathic pulmonary fibrosis (IPF). The official title of the trial, which is now listed at ClinicalTrials.gov, is “Efficacy and Safety of SAR156597 in the Treatment of Idiopathic…

A study led by researchers at the Imperial College London in the United Kingdom was recently published in the journal Nature reporting the discovery of a gene involved in pulmonary hypertension pathology. The study is entitled “The zinc transporter ZIP12 regulates the pulmonary…

Genentech recently announced in a statement that Esbriet (pirfenidone) has been recommended in the new American Thoracic Society’s (ATS) idiopathic pulmonary fibrosis (IPF) treatment guidelines. This recommendation, which is published as a resource for clinicians, is conditional and the ATS notes that healthcare providers should always discuss the pros…